PMID: 8584753Oct 20, 1995Paper

Intracerebroventricular administration of angiotensin type 1 (AT1) receptor antisense oligonucleotides attenuate thirst in the rat

Regulatory Peptides
R R SakaiSteven J Fluharty

Abstract

The central actions of the peptide hormone angiotensin II (AngII) are importantly involved in body fluid homeostasis. Included amongst these actions is a potent dipsogenic response that has been implicated in the thirst that develops during many forms of extracellular dehydration. The use of highly selective receptor antagonists has revealed that the Type 1 (AT1), and not the Type 2 (AT2), AngII receptor subtype mediates this drinking response. More recently, antisense oligonucleotides specific for the AT1 receptor have been developed and after intracerebroventricular (i.c.v.) administration, they significantly reduce the dipsogenic response elicited by a similar injection of AngII. In the present study AT1 antisense oligonucleotides were used to further investigate their effect on experimentally induced thirst in the rat. In addition, immunohistochemical analysis of biotin-labeled oligonucleotides was performed in order to correlate the behavioral effects of the oligonucleotides with their distribution in the brain. The results demonstrated that the antidipsogenic effects of the oligonucleotides were dose and time-dependent and were limited to those thirst challenges that involve activation of the renin-angiotensin system. Col...Continue Reading

References

Jan 1, 1978·Neuroendocrinology·M I Phillips
Dec 10, 1976·Science·E M StrickerR H McDonald
Aug 1, 1978·Journal of Comparative and Physiological Psychology·J B SimpsonJ S Camardo
Oct 1, 1978·Physiology & Behavior·J A HosuttE M Stricker
May 1, 1992·Neuroendocrinology·B P RoweR C Speth
Sep 1, 1970·The Journal of Physiology·A N EpsteinB J Rolls
Dec 1, 1971·Physiology & Behavior·K A Houpt, A N Epstein
Jan 1, 1993·Brain Research Bulletin·N E Rowland, M J Fregly

❮ Previous
Next ❯

Citations

May 10, 2003·Brain Research. Brain Research Reviews·Dirk Van OekelenJosée E Leysen
Sep 1, 1997·Neurochemistry International·I Neumann
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·S N IyerM K Raizada
Aug 30, 2008·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Eric LazartiguesRobin L Davisson
Sep 4, 2009·The Journal of Clinical Investigation·Stephen C BenoitDeborah J Clegg
Aug 30, 2008·Experimental Physiology·Derek DanielsSteven J Fluharty
Aug 19, 2009·The European Journal of Neuroscience·Peter W MarinelliA D Lê
Dec 24, 2011·Physiology & Behavior·Peter J VentoDerek Daniels
Oct 30, 2016·Physiology & Behavior·Bruce S McEwen
Dec 8, 2016·Physiology & Behavior·Stephen C WoodsDenovan P Begg
Apr 23, 2008·Current Protocols in Neuroscience·B G Hoebel, P J Wellman
Apr 7, 1999·Antisense & Nucleic Acid Drug Development·A W Szklarczyk, L Kaczmarek
May 12, 2004·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Lida ZavalaAnita Israel
May 29, 2014·Reviews in the Neurosciences·Yan A IvanenkovGleb I Filkov
Mar 14, 2014·Reviews in the Neurosciences·Anne QuiedevilleThomas Freret
Aug 27, 2005·Endocrinology·Derek DanielsSteven J Fluharty
Jul 17, 1999·The American Journal of Physiology·R MaW Wang
Apr 13, 2000·Cancer Control : Journal of the Moffitt Cancer Center·H H Engelhard
Jul 23, 1998·Physiological Reviews·J T Fitzsimons
Mar 15, 2001·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·R H WorckJ S Petersen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.